NCT05933876 The Impact of Radiotherapy on Oligometastatic Cancer
| NCT ID | NCT05933876 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Investigacio Sanitaria Pere Virgili |
| Condition | Metastasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2022-12-01 |
| Primary Completion | 2037-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2022-12-01 with a primary completion date of 2037-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Eligibility Criteria
Inclusion Criteria: * Histologic confirmation of primary tumor: breast, prostate, lung, colorectal. * 18 years old or older. * Up to five metastases located in the bone, lung, node, liver or brain. * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1. Exclusion Criteria: * Non-melanoma skin cancer. * Previous radiotherapy in the same anatomic location. * Presence of vascular collagen disease. * Pregnancy or lactation at the time of inclusion.
Contact & Investigator
Meritxell Arenas, PhD.
STUDY DIRECTOR
Universitat Rovira i Virgili, Hospital Universitari Sant Joan de Reus
Frequently Asked Questions
Who can join the NCT05933876 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05933876 currently recruiting?
Yes, NCT05933876 is actively recruiting participants. Contact the research team at jorge.joven@urv.cat for enrollment information.
Where is the NCT05933876 trial being conducted?
This trial is being conducted at Albacete, Spain, Barcelona, Spain, Barcelona, Spain, Barcelona, Spain and 11 additional locations.
Who is sponsoring the NCT05933876 clinical trial?
NCT05933876 is sponsored by Institut Investigacio Sanitaria Pere Virgili. The principal investigator is Meritxell Arenas, PhD. at Universitat Rovira i Virgili, Hospital Universitari Sant Joan de Reus. The trial plans to enroll 2,000 participants.